Tyrosine-protein kinase JAK2 inhibitors for the treatment of myeloproliferative neoplasms

Drugs of the Future

Volumn 35, Issue 8, 2010, Pages 651-660

  Majumder, A ^a   Sayeski, Peter P ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYT 387; HYDROXYUREA; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RUXOLITINIB; SB 1518; TG 101348; THALIDOMIDE; UNCLASSIFIED DRUG; XL 019;

ANEMIA; BALANCE DISORDER; BONE MARROW CANCER; BONE MARROW SUPPRESSION; CONFUSION; CYTOPENIA; DIARRHEA; DRUG EFFICACY; FORMICATION; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; IC 50; MYELOPROLIFERATIVE DISORDER; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOPENIA;

EID: 84952975945     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.08.1514131     Document Type: Review

References (74)

1. Giordanetto, F., Kroemer, R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 2002, 15(9): 727-37.
2. Saharinen, P., Silvennoinen, O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002, 277(49): 47954-63.
3. Saharinen, P., Takaluoma, K., Silvennoinen, O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000, 20(10): 3387-95.
4. Kampa, D., Burnside, J. Computational and functional analysis of the putative SH2 domain in Janus kinases. Biochem Biophys Res Commun 2000, 278(1): 175-82.
5. Girault, J.A., Labesse, G., Mornon, J.P., Callebaut, I. Janus kinases and focal adhesion kinases play in the 4.1 band: A superfamily of band 4.1 domains important for cell structure and signal transduction. Mol Med 1998, 4(12): 751-69.
6. Tanner, J.W., Chen, W., Young, R.L., Longmore, G.D., Shaw, A.S. The conserved box 1 motif of cytokine receptors is required for association with JAK kinases. J Biol Chem 1995, 270(12): 6523-30.
7. Zhao, Y., Wagner, F., Frank, S.J., Kraft, A.S. The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor beta c chain. J Biol Chem 1995, 270(23): 13814-8.
8. Feng, J., Witthuhn, B.A., Matsuda, T., Kohlhuber, F., Kerr, I.M., Ihle, J.N. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 1997, 17(5): 2497-501.
9. Kishimoto, T., Taga, T., Akira, S. Cytokine signal transduction. Cell 1994, 76(2): 253-62.
10. Taniguchi, T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995, 268(5208): 251-5.
11. Ihle, J.N. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol 1995, 60: 1-35.
12. Rane, S.G., Reddy, E.P. Janus kinases: Components of multiple signaling pathway. Oncogene 2000, 19(49): 5662-79.
13. Parganas, E., Wang, D., Stravopodis, D. et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93(3): 385-95.
14. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., Pfeffer, K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93(3): 397-409.
15. Lacronique, V., Boureux, A., Valle, V.D. et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278(5341): 1309-12.
16. Peeters, P., Raynaud, S.D., Cools, J. et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90(7): 2535-40.
17. Lacronique, V., Boureux, A., Monni, R. et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000, 95(6): 2076-83.
18. McWhirter, J.R., Galasso, D.L., Wang, J.Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993, 13(12): 7587-95.
19. Griesinger, F., Hennig, H., Hillmer, F. et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005, 44(3): 329-33.
20. Lane, S.W., Fairbairn, D.J., McCarthy, C., Nandini, A., Perry-Keene, J., Kennedy, G.A. Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion. Br J Haematol 2008, 142(4): 503.
21. Bousquet, M., Quelen, C., De Mas, V. et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005, 24(48): 7248-52.
22. Murati, A., Gelsi-Boyer, V., Adelaide, J. et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 2005, 19(9): 1692-6.
23. Reiter, A., Walz, C., Watmore, A. et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005, 65(7): 2662-7.
24. Malinge, S., Ben-Abdelali, R., Settegrana, C. et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007, 109(5): 2202-4.
25. James, C., Ugo, V., Le Couedic, J.P. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037): 1144-8.
26. Baxter, E.J., Scott, L.M., Campbell, P.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464): 1054-61.
27. Kralovics, R., Passamonti, F., Buser, A.S. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17): 1779-90.
28. Levine, R. L., Wadleigh, M., Cools, J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4): 387-97.
29. Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S.B., Zhao, Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280(24): 22788-92.
30. Wernig, G., Mercher, T., Okabe, R., Levine, R.L., Lee, B.H., Gilliland, D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107(11): 4274-81.
31. Lacout, C., Pisani, D.F., Tulliez, M., Gachelin, F.M., Vainchenker, W., Villeval, J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108(5): 1652-60.
32. Shide, K., Shimoda, H.K., Kumano, T. et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008, 22(1): 87-95.
33. Xing, S., Wanting, T.H., Zhao, W. et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008, 111(10): 5109-17.
34. Li, J., Spensberger, D., Ahn, J.S. et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010, Epub ahead of print.
35. Zhang, S.J., Li, J.Y., Li, W.D., Song, J.H., Xu, W., Qiu, H.X. The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Int J Lab Hematol 2007, 29(1): 71-2.
36. Schnittger, S., Bacher, U., Kern, W., Schroder, M., Haferlach, T., Schoch, C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 2006, 20(12): 2195-7.
37. Scott, L.M., Tong, W., Levine, R.L. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356(5): 459-68.
38. Zhao, L., Dong, H., Zhang, C.C. et al. A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J Biol Chem 2009, 284(39): 26988-98.
39. Pikman, Y., Lee, B.H., Mercher, T. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3(7): e270.
40. Pardanani, A.D., Levine, R.L., Lasho, T. et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 2006, 108(10): 3472-6.
41. Finazzi, G., Barbui, T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 2008, 22(8): 1494-502.
42. Beer, P.A., Green, A.R. Pathogenesis and management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2009, 621-8.
43. Vannucchi, A. M., Guglielmelli, P., Tefferi, A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009, 59(3): 171-91.
44. Rambaldi, A. Therapy of myelofibrosis (excluding JAK2 inhibitors). Int J Hematol 2010, 91(2): 180-8.
45. Meydan, N., Grunberger, T., Dadi, H. et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379(6566): 645-8.
46. Kleinberger-Doron, N., Shelah, N., Capone, R., Gazit, A., Levitzki, A. Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. Exp Cell Res 1998, 241(2): 340-51.
47. Deininger, M.W., Druker, B.J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003, 55(3): 401-23.
48. Lucet, I.S., Fantino, E., Styles, M. et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006, 107(1): 176-83.
49. Quintas-Cardama, A., Vaddi, K., Liu, P. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115(15): 3109-17.
50. Verstovsek, S., Kantarjian, H., Pardanani, A. et al. INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 558.
51. Verstovsek, S., Kantarjian, H.M., Pardanani, A.D. et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post- polycythemia/essential thrombocythemia myelofibrosis (post PV/ETMF). Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 1762.
52. Tefferi, A., Kantarjian, H.M., Pardanani, A.D. et al. The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1/2. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 2804.
53. Verstovsek, S., Kantarjian, H.M., Pardanani, A.D. et al. Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: No change in V617F:WT JAK2 ratio in patients with high allele burdens despite profound clinical improvement following treatment with the JAK inhibitor, INCB018424. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 2802.
54. Verstovsek, S., Kantarjian, H., Pardanani, A. et al. A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 7004.
55. Smith, B.D., Levis, M., Beran, M. et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103(10): 3669-76.
56. Knapper, S., Burnett, A.K., Littlewood, T. et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006, 108(10): 3262-70.
57. Hexner, E.O., Serdikoff, C., Jan, M. et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008, 111(12): 5663-71.
58. Santos, F.P., Kantarjian, H.M., Jain, N. et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010, 115(6): 1131-6.
59. Wernig, G., Kharas, M.G., Okabe, R. et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13(4): 311-20.
60. Geron, I., Abrahamsson, A.E., Barroga, C.F. et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008, 13(4): 321-30.
61. Lasho, T.L., Tefferi, A., Hood, J.D., Verstovsek, S., Gilliland, D.G., Pardanani, A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008, 22(9): 1790-2.
62. Pardanani, A.D., Gotlib, J., Jamieson, C. et al. TG101348, a JAK2-selective inhibitor, is well tolerated in patients with myelofibrosis and shows substantial therapeutic activity accompanied by a reduction in JAK2V617F allele burden. 14th Congr Eur Hematol Assoc (EHA) (June 4-7, Berlin) 2009, Abst 1088.
63. Pardanani, A.D., Gotlib, J., Jamieson, C. et al. A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 97.
64. Paquette, R., Sokol, L., Shah, N.P. et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 12(11): Abst 2810.
65. Shah, N.P., Olszynski, P., Sokol, L. et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 12(11): Abst 98.
66. Goh, K.C., Ong, W.C., Hu, C. et al. SB1518: A potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders. Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 10(11): Abst 538.
67. Pardanani, A., Lasho, T., Smith, G., Burns, C. J., Fantino, E., Tefferi, A. CYT387, a selective JAK1/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009, 23(8): 1441-5.
68. Tyner, J.W., Bumm, T.G., Deininger, J. et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms, Blood 2010, 115(25): 5232-40.
69. James, C. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: One mutation for three diseases? Hematology Am Soc Hematol Educ Program 2008, 69-75.
70. Kilpivaara, O., Mukherjee, S., Schram, A.M. et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009, 41(4): 455-9.
71. Olcaydu, D., Harutyunyan, A., Jager, R. et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009, 41(4): 450-4.
72. Jones, A.V., Chase, A., Silver, R.T. et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009, 41(4): 446-9.
73. Vannucchi, A.M., Guglielmelli, P., Rambaldi, A., Bogani, C., Barbui, T. Epigenetic therapy in myeloproliferative neoplasms: Evidence and perspectives. J Cell Mol Med 2009, 13(8A): 1437-50.
74. Williams, N.K., Bamert, R.S., Patel, O. et al. Dissecting specificity in the Janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 2009, 387(1): 219-32.